Levothyroxine Sodium Tablets Recalled Nationwide for Potency Variance
Mylan Institutional recalls 1,133 cartons of Levothyroxine Sodium Tablets (137 mcg) nationwide. Three lots contain subpotent and superpotent tablets.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a prescription thyroid hormone medication. Potency variance poses a risk of incorrect dosing to patients nationwide, but no illnesses or hospitalizations are reported in the source text.
Plain-English summary
Mylan Institutional, Inc. is recalling 1,133 cartons of Levothyroxine Sodium Tablets, USP, 137 mcg (NDC 42292-041-20). The product is a prescription medication supplied as 100 tablets per carton in 10 unit-dose blister cards, manufactured for Mylan Pharmaceuticals Inc. in Morgantown, West Virginia.
The recall affects three specific lots: #3115448 (expiration 12/31/2024), #3115732 (expiration 3/31/2025), and #3116024 (expiration 9/30/2025). These lots contain subpotent and superpotent tablets, meaning the levothyroxine sodium content varies from the stated 137 mcg dose.
The recalled product was distributed nationwide in the United States.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- Mylan Institutional, Inc.
- Category
- Drug — Thyroid Medication
- Hazard
- subpotency
- superpotency
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot #: 3115448
- Exp. Date 12/31/2024
- 3115732
- Exp. Date 3/31/2025
- 3116024
- Exp. Date 9/30/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LEVOTHYROXINE SODIUM
- HighLevothyroxine Sodium Tablets Recalled for Out-of-Specification Potency
FDA (Drugs) · 2025-03-26
- HighFDA Recalls Super-Potent Levothyroxine Sodium Tablets Due to Potency Deviation
FDA (Drugs) · 2025-03-26
- HighLevothyroxine Sodium tablets recalled for impurity specification failure
FDA (Drugs) · 2025-01-08
- HighLevothyroxine Sodium Tablets Recalled for Subpotent and Superpotent Content
FDA (Drugs) · 2024-12-18
- HighFDA Recalls Levothyroxine Sodium Tablets for Potency Variation
FDA (Drugs) · 2024-12-18
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27